Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Macitentan/Tadalafil Fixed-Dose Combination
NCT04540744Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration, Area Under the Concentration-time Curve from Time Zero to the Last Quantifiable Concentration and 1 more. Started Apr 2021; status: completed.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04540744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540744.